CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Pharmacologic inhibitors targeting cyclin-dependent kinases 4 and 6 (CDK4/6) are primarily used to induce cancer cell cycle arrest.
• Emerging evidence suggests CDK4/6 inhibitors also modulate cancer cell immunogenicity, apoptosis, and differentiation.

Purpose of the Study:

• To investigate the mechanisms by which CDK4/6 inhibitors influence cancer cell phenotypes beyond cell cycle arrest.
• To elucidate the role of chromatin remodeling and enhancer activation in mediating these effects.

Main Methods:

• Utilized cell-based and mouse models of breast cancer.
• Analyzed clinical specimens.
• Investigated chromatin remodeling and enhancer activity.
• Assessed transcription factor protein levels, including Activator Protein-1 (AP-1).

Main Results:

• CDK4/6 inhibitors induce significant cancer cell chromatin remodeling with widespread enhancer activation.
• Activated enhancers include super-enhancers promoting luminal differentiation and apoptotic evasion.
• A distinct set of enhancers near endogenous retroviral elements, enriched for interferon-driven genes, were also identified.
• CDK4/6 inhibition increases Activator Protein-1 (AP-1) protein levels, contributing to enhancer activity.

Conclusions:

• CDK4/6 inhibitors induce pleiotropic effects through chromatin remodeling and enhancer activation.
• Findings provide novel insights into CDK4/6 pathway biology.
• Results may guide the future development of CDK4/6 inhibitors in cancer therapy.